Investigators trialed injection of an immune-stimulating substance (poly-ICLC) into the prostate gland using MRI-ultrasound fusion technology in patients scheduled to undergo radical prostatectomy.

The FDA approved a larger nelarabine vial to improve dosing flexibility and simplify treatment for adult and pediatric ...

Swiss pharma giant Roche Holding AG's RHHBY 2025 results were affected by currency headwinds. Sales totaled $74.4 billion, which missed the Zacks Consensus Estimate of $81.4 billion. Earnings per ...

Ozempic has become so embedded in global culture that “Ozempic face” was shortlisted for a prominent dictionary’s word of the year in 2025. Ozempic isn’t the only drug that mimics the natural GLP-1 ...

Reinforces Synergistic Potential and Expands Opportunity Beyond Ovarian Cancer VANCOUVER, BC - January 29, 2026 (NEWMEDIAWIRE) - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB:BVAXF) ...

Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has approved the company’s oncology drug, Nelarabine Injection, ...

Moderna and Merck's melanoma vaccine, combined with Keytruda, could halve cancer recurrence risk, marking a breakthrough in ...

Roche is looking to a busy 2026 after 10 new molecules entered late-stage testing last year and as a potential launch of ...

Thousands of Palestinian cancer patients are living without treatment as they await medical evacuation ...

Emerging immunotherapies and targeted therapies take aim at recently identified biomarkers ...

‘Doctors laughed off my cancer fears – then I got my diagnosis at 24’ - Kelly Underwood first presented with lethargy, sore ...

A newly identified metabolite in human feces improves immunotherapy and could radically change the treatment of lung cancer.